

ANTEOTECH SIGNS COMMERCIAL CONTRACT WITH IMRA AMERICA INC.

18th November 2019

Surface chemistry and coating Company AnteoTech Limited (ASX: ADO) (“AnteoTech” or “the Company”) is pleased to announce it has signed a commercial agreement with IMRA America Inc (“IMRA”), for joint production and marketing of AnteoBind coated IMRA 40nm i-colloid gold particles for use in lateral flow assays in the point of care (PoC) diagnostic market.

IMRA is an established company and recognised brand in the lateral flow assay market and has extensive global marketing and distribution capability. It counts multiple PoC testing developers as customers. IMRA’s nano bio division manufactures gold and gold-alloy nanoparticle products and develops functionalised derivatives that enable efficient and versatile assay design and development.

Under the agreement, AnteoTech will activate the IMRA i-colloid gold particles with AnteoBind. The combined product will be branded and marketed as an IMRA particle “powered by AnteoBind” and will be distributed via IMRA’s extensive global distribution network. Initial sales exposure into the IMRA network will provide Anteo with a potential compounding effect for additional partnerships.

The joint product will combine two complementary and established tools used in lateral flow assay development and will provide a pre-activated easy-to-use, easy-to-procure particle for rapid testing and development. We expect the uptake of the product to grow with strong marketing and successful end-customer use.

This agreement comes after a lengthy period of development and testing by AnteoTech and IMRA. During this time, IMRA became increasingly confident in the binding qualities of AnteoBind and the development capability of the AnteoTech team. This confidence, together with the current agreement has led to a new set of collaboration activity with IMRA investigating production of AnteoBind powered versions of a number of other particles in IMRA’s range. This partnership reinforces the company strategy and the recent ISO9001 accreditation to maintain the highest quality management systems for our partners.

AnteoTech’s Chief Executive Officer Derek Thomson commented, “This is indeed an important commercial partnership for AnteoTech and our broad PoC strategy. It is undoubtedly a powerful endorsement and validation of our product and capability by a very reputable company in the PoC industry. The opportunity to co-brand with IMRA will further enhance our standing and reputation in the industry and support other similar opportunities already in our pipeline.”

“I congratulate Dr. Charlie Huang and his team for outstanding R&D work. We are delighted to have forged such a strong partnership and I look forward to working with the team to broaden our relationship with IMRA.

“We have excellent momentum across AnteoTech in both our Life Sciences and Battery divisions and our commercial pipeline is building favourably. Our strategy of pursuing collaborations with partners that will co-fund R&D with AnteoTech is gathering momentum and this is an important building block in establishing sustainable revenue streams prior to commercial sales materialising. I look forward to reporting on further successes.”

AnteoTech Ltd ACN 070 028 625

Unit 4, 26 Brandl St, Eight Mile Plains, QLD 4113,

Australia p: +61 7 3219 0085 f: +61 7 3219 0553

contact@anteotech.com www.anteotech.com

For personal use only



ABOUT ANTEO GROUP – AnteoTech Limited (ADO:ASX)

AnteoTech (formerly Anteo Diagnostics Ltd) is a surface chemistry company with Intellectual Property (“IP”) in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company’s purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

ABOUT IMRA AMERICA Inc.

IMRA America was founded in 1990 in Ann Arbor, MI and has become a key member of a global set of companies anchored by the All AISIN Group of Japan, which is the world’s third largest manufacturer of automotive components. IMRA America is dedicated to creative research and innovation leading to the development of essential technologies for future industrial use.

For more information, please contact:

Derek Thomson, Chief Executive Officer, Anteo Diagnostics Limited: +61 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

Follow AnteoTech on Twitter: <https://twitter.com/AnteoDX> or visit www.anteotech.com

For personal use only

